Welcome to the GoodRx third-quarter 2024 earnings call. As a reminder, today's conference call is being recorded. I would now ...

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with ...

GoodRx shares rose 1.5% in premarket trading Tuesday after the healthcare company said it will offer a 30-day supply of oral ...

VIVUS announced today that the U.S. Food and Drug Administration has removed the requirement for a cardiovascular outcome trial for its weight-management medication QSYMIA (phentermine and ...

Topamax contains the active ingredient topiramate. This is also one of the active ingredients in Qsymia, an FDA-approved drug for long-term weight management. (The other active ingredient in ...

One in five adults and one in four young adults (12-17) experience weight loss on the top dose of QSYMIA of at least 20% of ...

One in five adults and one in four young adults (12-17) experience weight loss on the top dose of QSYMIA of at least 20% of their body weight. Our partnership with GoodRx coupled with the weight ...

CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and Drug Administration has removed the requirement for a cardiovascular outcome trial for its ...

GoodRx has officially entered the weight loss drug market by offering an exclusive discount on the once-daily oral medication Qsymia.